Searching journal content for chemotherapy (as phrase) in full text.

Displaying results 1-10 of 566
For checked items
  1. Review:
    • Yulong Li and
    • William F Simonds
    Endocrine neoplasms in familial syndromes of hyperparathyroidism Endocr Relat Cancer 23 (6) R229-R247, doi:10.1530/ERC-16-0059 first published on 20 May 2016
    ...not sensitive to radiation therapy or chemotherapy. Successful immunotherapy using intradermal...poorly to platinum-based cytotoxic chemotherapy. Streptozocin, 5-flurouracil...differentiated pNET may be treated by chemotherapy with platinum-based regimen (cisplatin...
  2. Research:
    • Régia Caroline Peixoto Lira,
    • Paola Fernanda Fedatto,
    • David Santos Marco Antonio,
    • Letícia Ferro Leal,
    • Carlos Eduardo Martinelli,
    • Margaret de Castro,
    • Silvio Tucci,
    • Luciano Neder,
    • Leandra Ramalho,
    • Ana Luiza Seidinger,
    • Izilda Cardinalli,
    • Maria José Mastellaro,
    • José Andres Yunes,
    • Silvia Regina Brandalise,
    • Luiz Gonzaga Tone,
    • Sonir Roberto Rauber Antonini,
    • and Carlos Alberto Scrideli
    IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis Endocr Relat Cancer 23 (6) 481-493, doi:10.1530/ERC-15-0426 first published on 16 May 2016
    ...et al. 2012). Adjuvant mitotane, chemotherapy and/or radiotherapy have been often...nephrectomy due to Wilms tumor, before chemotherapy and from children without Beckwith-Wiedemann...Jarzab B et al. 2012 Combination chemotherapy in advanced adrenocortical carcinoma...
  3. Research Letter:
    • Bertrand Brieau,
    • Olivia Hentic,
    • Rachida Lebtahi,
    • Maxime Palazzo,
    • Makrem Ben Reguiga,
    • Vinciane Rebours,
    • Frederique Maire,
    • Pascal Hammel,
    • Philippe Ruszniewski,
    • and Pierre Fenaux
    High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy Endocr Relat Cancer 23 (5) L17-L23, doi:10.1530/ERC-15-0543 first published on 1 March 2016
    ...heavily pretreated with alkylating chemotherapy Bertrand Brieau 1 Olivia Hentic 1 Rachida...disease stage, after alkylating-based chemotherapy. Our study included all 20 consecutive...and generally after first-line chemotherapy. As defined in previous reports from...
  4. Research:
    • J R Strosberg,
    • M Cives,
    • J Hwang,
    • T Weber,
    • M Nickerson,
    • C E Atreya,
    • A Venook,
    • R K Kelley,
    • T Valone,
    • B Morse,
    • D Coppola,
    • and E K Bergsland
    A phase II study of axitinib in advanced neuroendocrine tumors Endocr Relat Cancer 23 (5) 411-418, doi:10.1530/ERC-16-0008 first published on 14 April 2016
    ...received prior octreotide LAR, four received prior cytotoxic chemotherapy (including etoposide/cisplatin and capecitabine/temozolomide...Range 1-3 Previous systemic therapy Octreotide LAR 27 90 Chemotherapy 4 13 Everolimus 3 10 Interferon-alpha 3 10 PRRT 1 3 Investigational...
  5. Research:
    • Vinciane Corman,
    • Iulia Potorac,
    • Florence Manto,
    • Sarah Dassy,
    • Karin Segers,
    • Albert Thiry,
    • Vincent Bours,
    • Adrian F Daly,
    • and Albert Beckers
    Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation Endocr Relat Cancer 23 (5) 391-397, doi:10.1530/ERC-16-0057 first published on 21 March 2016
    ...months after surgery, when local recurrence was diagnosed at the site of the mastectomy scar. Radiation therapy and adjuvant chemotherapy (epirubicin plus cyclophosphamide, with paclitaxel) were instituted. Genetic analysis of the BRCA1 and BRCA2 genes was...
  6. Research:
    • Tanja Ignatov,
    • Holm Eggemann,
    • Elke Burger,
    • Serban Dan Costa,
    • and Atanas Ignatov
    Hormone receptor status does not alter the effect of trastuzumab in breast cancer Endocr Relat Cancer 23 (5) 349-355, doi:10.1530/ERC-16-0084 first published on 23 March 2016
    ...response rate to first-line trastuzumab and chemotherapy, but with improved progression-free survival...HR disease receiving adjuvant trastuzumab and chemotherapy or only chemotherapy were 81.6 and 73.0%, respectively, and...
  7. Review:
    • David Viola,
    • Laura Valerio,
    • Eleonora Molinaro,
    • Laura Agate,
    • Valeria Bottici,
    • Agnese Biagini,
    • Loredana Lorusso,
    • Virginia Cappagli,
    • Letizia Pieruzzi,
    • Carlotta Giani,
    • Elena Sabini,
    • Paolo Passannati,
    • Luciana Puleo,
    • Antonio Matrone,
    • Benedetta Pontillo-Contillo,
    • Valentina Battaglia,
    • Salvatore Mazzeo,
    • Paolo Vitti,
    • and Rossella Elisei
    Treatment of advanced thyroid cancer with targeted therapies: ten years of experience Endocr Relat Cancer 23 (4) R185-R205, doi:10.1530/ERC-15-0555
    ...external beam radiotherapy (EBRT) and chemotherapy, have been unsuccessfully employed...despite the relevant toxic effects of chemotherapy, studies have shown that they have...previously treated with other TKIs or chemotherapy. At the data cutoff point, patients...
  8. Review:
    • Jamie L Van Etten and
    • Scott M Dehm
    Clonal origin and spread of metastatic prostate cancer Endocr Relat Cancer 23 (4) R207-R217, doi:10.1530/ERC-16-0049 first published on 21 March 2016
    ...splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant...in metastatic prostate cancer before chemotherapy. New England Journal of Medicine 371...metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 368...
  9. Research:
    • Catia Mio,
    • Elisa Lavarone,
    • Ketty Conzatti,
    • Federica Baldan,
    • Barbara Toffoletto,
    • Cinzia Puppin,
    • Sebastiano Filetti,
    • Cosimo Durante,
    • Diego Russo,
    • Arturo Orlacchio,
    • Antonio Di Cristofano,
    • Carla Di Loreto,
    • and Giuseppe Damante
    MCM5 as a target of BET inhibitors in thyroid cancer cells Endocr Relat Cancer 23 (4) 335-347, doi:10.1530/ERC-15-0322 first published on 24 February 2016
    ...BETis or vehicle (NT). Caspase 3/7 levels were normalized to the vehicle-treated group. Temozolomide (500muM), a chemotherapy drug, was used as a positive control for apoptosis. Each sample was run in triplicate. *P 0.05, ***P 0.001...
  10. Research:
    • María Rodríguez-Sanz,
    • Daniel Prieto-Alhambra,
    • Sonia Servitja,
    • Natalia Garcia-Giralt,
    • Laia Garrigos,
    • Jaime Rodriguez-Morera,
    • Joan Albanell,
    • Maria Martínez-García,
    • Iria González,
    • Adolfo Diez-Perez,
    • Ignasi Tusquets,
    • and Xavier Nogués
    AI-related BMD variation in actual practice conditions: A prospective cohort study Endocr Relat Cancer 23 (4) 303-312, doi:10.1530/ERC-16-0025 first published on 24 February 2016
    ...or 1 month after the last cycle of chemotherapy, or alternatively, after 2, 3...menopause, parity, lactation, previous chemotherapy and radiotherapy, adjuvant treatments...34.6%) 71 (39.7%) Prior chemotherapy n (%) 298 (58.9%) 106 (59...
For checked items

Search Results

Next 10 » New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. May 2016, 23 (5)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most